Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Astellas Pharma
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 4 ans
A study to compare the blood levels of Tacrolimus in children who already have a transplant when they are switched from anti-rejection therapy with Prograf to therapy with Advagraf, including checking safety and effectivity over a longer period after switching
To compare the steady state AUC0-24h of tacrolimus for Advagraf® with that of Prograf® in stable pediatric allograft recipients after 1:1 (mg:mg) conversion from Prograf® to Advagraf®
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma GmbH
MAJ Il y a 4 ans
A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE LIVER TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEN
To assess the safety of a tacrolimus modified release, MR4 , based immunosuppressive regimen in stable liver transplant subjects converted on a 1:1 (mg:mg) basis from a Prograf® based immunosuppressi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 4 ans
A study of an approved granule formulation of tacrolimus to examine the absorption and excretion by the body of newly transplanted paediatric patients
To determine the pharmacokinetics (PK) of tacrolimus following oral administration of Modigraf®, after the first oral dose and at steady state in paediatric subjects undergoing de novo allograft tran...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 4 ans
Protocol for Phase IIb Study of YM150. A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Compare YM150 bid and qd Doses and Enoxaparin for Prevention of Venous Thromboembolism in Subjects Undergoing Elective Hip Replacement Surgery. A Phase IIb study to Evaluate the Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects undergoing Elective Hip Replacement Surgery
The primary objective is to evaluate the efficacy and safety of 15 mg bid, 30 mg qd, 30 mg bid and 60 mg qd YM150 and to compare efficacy and safety with enoxaparin 40 mg qd, in subjects undergoing el...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma GmbH
MAJ Il y a 4 ans
A phase II, open-label, multi-centre study to assess the effect of single and multiple oral doses (1 mg, 2 mg, and 3 mg) of everolimus on the pharmacokinetics of tacrolimus in stable renal transplant patients
The objective of this study is to obtain information on the pharmacokinetics of tacrolimus when used in combination with everolimus in stable kidney transplant patients.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Global Development, Inc (APGD)
MAJ Il y a 4 ans
A Phase 3b Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients with Recent Onset Symptomatic Atrial Fibrillation
The primary safety objective of this study is to evaluate the safety of vernakalant injection in subjects with recent onset (AF > 3 hours to less than or equal to 7 days), symptomatic atrial fibrillat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 4 ans
This is a multinational research study comparing liquid or tablets of medicine Fidaxomicin versus liquid or capsules of medicine Vancomycin in children having Diarrhea caused with bacteria named Clostridium difficile
The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium diff...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Global Development, Inc (APGD)
MAJ Il y a 4 ans
A clinical study (Phase III) to assess the Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT), when compared against placebo in a randomised, double blind manner
• To evaluate the efficacy of ASP0113 compared with placebo as measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD) through one year post-transplant. • To eval...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 4 ans
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF A FOUR-WEEK TREATMENT WITH YM758 IN SUBJECTS WITH STABLE ANGINA
To assess the safety and tolerability of different oral doses of YM758 in subjects with stable angina.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe
MAJ Il y a 4 ans
Ureteric stent in kidney transplantation
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
3
4
5
6
7
8
9
10
11
12
Suivant